Oncology Brothers · @OncBrothers“Amivantamab (SC) now @FDA✅ for 2L R/M HNSCC (HPV-unrelated) post plat + IO based on #OrigAMI4: - Ph1b/2, SC Ami mono (n=102) - ORR 42% (CR 15%). Historic 2L ORR 20-25% - mPFS 6.8mos, mOS 12.5mos - DoR NR (56% ≥6mo)! Much needed option. #OncTwittwer @OncUpdates @OncoAlert https://t.co/l6IF5AJf9E”
View post ↗FDA grants accelerated approval to Rybrevant Faspro in R/M HNSCC →The ONWARD consortium's real-world tarlatamab cohort from 11 US centers in SCLC (JTO) reported real-world PFS of 2.3 months and OS of 8.0 months, with no PFS difference by brain metastasis status (44.5% had brain metastases). CRS occurred in 40.8% (grade 3–4, 3.8%) and ICANS in 21.5% (grade 3–4, 6%), and CRS was 5.3% with prophylactic tocilizumab vs 43.0% without. Early data on tarlatamab beyond SCLC, in atypical carcinoid and LCNEC, also drew attention.
“Real-world tarlatamab in SCLC: ONWARD consortium, 11 US centers”
— @HHorinouchi · ONWARD real-world tarlatamab · View post ↗📌 Amplified by @KolPulseAI
“Early data for DLL3-targeted therapy beyond SCLC.”
— @lungoncdoc · Tarlatamab beyond SCLC · View post ↗📌 Amplified by @KolPulseAI
“It divides each fraction into Inhale and Exhale delivery techniques to mitigate the risk of chest wall pain.”
— @DrewMoghanaki · Split-course SBRT · View post ↗Dr. Yakup Ergün highlighted a 42-patient single-arm phase 1b/2 study of the PD-L1×VEGF-A bispecific pumitamig plus nab-paclitaxel in first-line metastatic TNBC, with investigator-assessed ORR 73.8%, median PFS 13.5 months, median OS 33.4 months, ORR 65.5% in CPS <10 and grade ≥3 treatment-related toxicity of 60%, in patients with no prior immunotherapy. Pumitamig is investigational. Dr. Yara Abdou's new JAMA Oncology paper mapped the expanding first-line options in HER2+ metastatic breast cancer. Slides from Meritxell Bellet's ESMO26 presentation on the pathology of lobular vs no-special-type breast cancer also circulated.
“The results are really striking.”
— @dr_yakupergun · Pumitamig in TNBC · View post ↗📌 Amplified by @KolPulseAI
“With more options than ever, the key question is: Who needs what, and how much treatment is enough?”
— @YAbdouMD · First-line HER2+ MBC · View post ↗Dr. Arndt Vogel shared the 5-year follow-up of CheckMate 648 in Annals of Oncology, comparing nivolumab plus chemotherapy or nivolumab plus ipilimumab with chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma, which he described as showing a clinically meaningful OS benefit over chemotherapy. Dr. Raghav Sundar's new Clinical Cancer Research paper examined Claudin18.2 and tumor microenvironment components such as B cells as predictors of response in gastroesophageal cancer. Dr. Common Sense Oncology announced a November 16 critical appraisal of RASolute 302 and of how daraxonrasib pricing will affect access.
“Nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: 5-year follow-up results from CheckMate 648”
— @ArndtVogel · CheckMate 648 5-year OS · View post ↗📌 Amplified by @KolPulseAI
“We describe the role of Claudin18.2 and components of the TME such as B-cells as predictors of response to treatment and cancer progression in gastroesophageal cancer”
— @sundar__raghav · Claudin18.2 and the TME · View post ↗
“Join CSO on November 16th for a critical appraisal of the RASolute 302 trial, followed by a discussion of how the pricing of daraxonrasib will impact patient access.”
— @csoncol · RASolute 302 appraisal · View post ↗Track oncology’s top KOLs in your specialty
Create a free account, pick the tumor types you cover, and go beyond the tweet — the intelligence pharma teams use to map influence and prepare for engagement:
- ✓Enhanced KOL profiles
- ✓Pharma influence & potential advisory-board patterns
- ✓2025 Open Payments financial analysis
- ✓Social-media sentiment & trend signals
Dr. Toni Choueiri shared a Lancet Oncology analysis of 1,049 patients with RCC brain metastases treated in 2016–2022: median OS was 20.0 months vs 9.6 and 12.0 months in legacy cohorts, and the updated Renal GPA stratified median survival from 4.8 to 51.2 months. Dr. Enrique Grande noted these are retrospective data. Dr. Laura Bukavina highlighted the largest contemporary series of de novo urothelial atypia of unknown significance (n=103), with a 5-year bladder cancer risk of 6.5% and median time to progression of 1.7 years. EMUC26 posts covered Nectin-4 PET in urothelial cancer and PSMA PET timing after radiotherapy for prostate cancer.
“Important message: brain metastases should not automatically exclude patients from clinical trials.”
— @DrChoueiri · RCC brain metastases · View post ↗
“Retrospective data.”
— @drenriquegrande · Renal GPA · View post ↗
“Perhaps scoping again in 1-2 years may not be a bad idea”
— @LauraBukavinaMD · Urothelial atypia · View post ↗Dr. Vincent Rajkumar will present the final AQUILA overall survival results at ASH 2026: daratumumab monotherapy significantly improved OS vs active monitoring in high-risk smoldering multiple myeloma (HR 0.52; 95% CI 0.32–0.87; P=0.0108), with 7-year OS of 87.8% vs 78.7%. @Papa_Heme compared the 6-year OS of 86% with DRVd in PERSEUS to the 79% 7-year OS he cited for AQUILA and questioned the therapy control-arm patients received after progressing to myeloma. Dr. Larry Anderson's IPTW analysis compared teclistamab plus daratumumab with daratumumab-based proteasome inhibitor combinations in relapsed/refractory myeloma. ASH 2026 abstracts went online this week.
“AQUILA results have already changed practice widely all over the world establishing daratumumab for 3 years as early intervention option for high risk smoldering myeloma.”
— @VincentRK · AQUILA OS · View post ↗📌 Amplified by @KolPulseAI
“The much higher overall survival for those with myeloma with DRVd in PERSEUS (6 year OS=86%) compared to observed with smoldering myeloma in AQUILA trial (7 year OS=79%) speaks volumes about horrible therapy patients in control arm of AQUILA received when they developed myeloma”
— @Papa_Heme · AQUILA vs PERSEUS · View post ↗📌 Amplified by @KolPulseAI
“Here in Kansas this has been the SOC!”
— @Abdallah81MD · AQUILA OS · View post ↗
“What would Voltaire say about optimizing bridging before CAR-T therapy in multiple myeloma?”
— @RahulBanerjeeMD · CAR-T bridging · View post ↗📌 Amplified by @KolPulseAI
“Since 90.7% of SOC in Tec-3 was Pom after prior Rev, we looked at more PI based ctrls (DKd from CANDOR, DVd from CASTOR) with IPTW, and we see the same increase in all outcomes (CR, PFS, OS) with Tec/Dara.”
— @ldandersonjr · Teclistamab + daratumumab IPTW · View post ↗📌 Amplified by @KolPulseAI
“I will have two oral presentations from our centre one on the possibility of cure in myeloma patients and another on the evolving definition of functional high risk myeloma”
— @thanosdimop · ASH26 orals · View post ↗📌 Amplified by @KolPulseAI
With ASH 2026 abstracts now public, Dr. Chris Hourigan highlighted MEASURE, a national prospective protocol to validate whole-genome-sequencing-informed AML MRD testing, and an ASH abstract achievement award for dPCR-based MRD work in KMT2A-rearranged leukemia from the same study. Dr. Hayder Saeed flagged a first-in-human in vivo CD19 CAR T (SNC116, investigational) given without lymphodepletion in relapsed/refractory B-cell NHL: ORR 5/6 and CR 4/6, with no grade ≥3 CRS or ICANS. A study in large B-cell lymphoma linked tumor CD19 expression to distinct outcomes after CD19 CAR T, and an ASH26 oral abstract on macrocyclization of BTK inhibitors to overcome resistance in CLL drew attention.
“MEASURE, the national prospective clinical protocol to validate WGS-informed AML MRD testing, is no longer under @ASH_hematology embargo!”
— @DrChrisHourigan · AML MRD · View post ↗
“Tiny, early. If it holds, CAR T logistics change.”
— @HayderSaeed_MD · In vivo CD19 CAR T · View post ↗